RE:RE:RE:RE:RE:RE:It's all about efficacy % as this what will lead us to a jv Rumpl3 ... So far, with regards to efficacy %, we cannot state this with enough statistical significance. Too early yet. The next update can be a game changer though.
Have you seen the CG0070
efficacy data? On how many patients? You still don't know their final numbers.
Have you seen the ImmunityBio
efficacy data? We know their final numbers.
We all know about TLD1433 key strengths and its potential. And we all wish it becomes the next GOTO treatment. But we don't know yet our final efficacy % range. That's why we have a very nice sample (11 patients) to focus on. It can reveal us a lot.
So potential has to turn into statistical significance on the efficacy % aspect for it to become solid input for discussions with a big pharma, so it can be easier to convince any urologists, fasten market penetration. And has to stay superior to others. We're getting closer, but we're not there yet. Lets analyse the next round of data. It can be pivotal.
_________________
Rumpl3StiltSkin - (8/23/2022 1:46:32 PM)
RE:RE:RE:RE:RE:It's all about efficacy % as this what will lead us to a jv
Yep, I agree with ya there Skys, I was talking about CR/PR %s of 1433 vs Keytruda + other Combo therapies. Of course TLT, as a stand alone, also beats them there.